Skip to Content

Disease Modification

The Benefits of and Considerations for Using Disease-Modifying Therapies (DMTs) for Multiple Sclerosis

  • injectable therapies." c-nmssatomrichtext_nmssatomrichtext-host="">
    Self-injectable DMTs include:
    • Glatiramer acetate (Copaxone®, glatiramer acetate injection, Glatopa®)
    • Interferon beta-1a (Avonex®,Betaseron®, Extavia®, Rebif®)
    • Peginterferon beta-1a (Plegridy®)
    • Ofatumumab (Kesimpta®)
    Learn more about injectable therapies.

  • oral therapies." c-nmssatomrichtext_nmssatomrichtext-host="">
    Oral therapies include:
    • Cladribine (Mavenclad®)
    • Dimethyl fumarate (Tecfidera®)
    • Diroximel fumerate (Vumerity®)
    • Fingolimod (Gilenya®, Tascenso ODT®)
    • Monomethyl fumarate (Bafiertam™)
    • Ozanimod (Zeposia®)
    • Ponesimod (Ponvory™)
    • Siponimod (Mayzent®)
    • Teriflunomide (Aubagio®)
    Learn more about oral therapies.

  • infused therapies." c-nmssatomrichtext_nmssatomrichtext-host="">
    Infused DMTs include:
    • Alemtuzumab (Lemtrada®)
    • Mitoxantrone (Novantrone®)
    • Natalizumab (Tysabri®)
    • Natalizumab-sztn (Tyruko®)
    • Ocrelizumab (Ocrevus®)
    • Ublituximab-xiiy (Briumvi™)
    Learn more about infused therapies.

"off-label" use.

American Academy of Neurology Practice Guideline for the Use of DMTs

In September 2021, the American Academy of Neurology (AAN) reaffirmed its practice guideline for the use of disease-modifying therapies for adults with MS. These guidelines have been endorsed by the National Multiple Sclerosis Society and the Multiple Sclerosis Association of America. The guidelines address starting, switching and stopping DMTs for adults living with MS. The full guidelines and summaries are available for clinicians and patients." c-nmssatomrichtext_nmssatomrichtext-host="">
Under certain circumstances, some healthcare providers may use medications to treat MS that have FDA approval for other diseases, sometimes referred to as "off-label" use.

American Academy of Neurology Practice Guideline for the Use of DMTs

In September 2021, the American Academy of Neurology (AAN) reaffirmed its practice guideline for the use of disease-modifying therapies for adults with MS. These guidelines have been endorsed by the National Multiple Sclerosis Society and the Multiple Sclerosis Association of America. The guidelines address starting, switching and stopping DMTs for adults living with MS. The full guidelines and summaries are available for clinicians and patients.
Guidelines for Disease-Modifying Therapies for MS From the American Academy of Neurology